Trade Genprex, Inc. - GNPX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0072 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Genprex Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 0.3734 |
| Open* | 0.3855 |
| 1-Year Change* | -72.66% |
| Day's Range* | 0.3754 - 0.3934 |
| 52 wk Range | 0.43-1.94 |
| Average Volume (10 days) | 270.61K |
| Average Volume (3 months) | 15.09M |
| Market Cap | 30.06M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 59.41M |
| Revenue | N/A |
| EPS | -0.61 |
| Dividend (Yield %) | N/A |
| Beta | -0.15 |
| Next Earnings Date | Nov 14, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 29, 2023 | 0.3884 | 0.0029 | 0.75% | 0.3855 | 0.3945 | 0.3754 |
| Sep 28, 2023 | 0.3734 | -0.0100 | -2.61% | 0.3834 | 0.3869 | 0.3664 |
| Sep 27, 2023 | 0.3684 | -0.0160 | -4.16% | 0.3844 | 0.4002 | 0.3666 |
| Sep 26, 2023 | 0.3908 | 0.0134 | 3.55% | 0.3774 | 0.3984 | 0.3774 |
| Sep 25, 2023 | 0.3774 | 0.0055 | 1.48% | 0.3719 | 0.3935 | 0.3676 |
| Sep 22, 2023 | 0.3747 | -0.0296 | -7.32% | 0.4043 | 0.4214 | 0.3747 |
| Sep 21, 2023 | 0.4217 | -0.0230 | -5.17% | 0.4447 | 0.4464 | 0.4097 |
| Sep 20, 2023 | 0.4414 | -0.0003 | -0.07% | 0.4417 | 0.4595 | 0.4389 |
| Sep 19, 2023 | 0.4440 | -0.0046 | -1.03% | 0.4486 | 0.4576 | 0.4424 |
| Sep 18, 2023 | 0.4387 | -0.0397 | -8.30% | 0.4784 | 0.4866 | 0.4387 |
| Sep 15, 2023 | 0.4873 | -0.0262 | -5.10% | 0.5135 | 0.5135 | 0.4824 |
| Sep 14, 2023 | 0.5077 | -0.0037 | -0.72% | 0.5114 | 0.5242 | 0.5076 |
| Sep 13, 2023 | 0.5125 | -0.0241 | -4.49% | 0.5366 | 0.5384 | 0.5124 |
| Sep 12, 2023 | 0.5332 | 0.0248 | 4.88% | 0.5084 | 0.5427 | 0.5084 |
| Sep 11, 2023 | 0.5111 | -0.0053 | -1.03% | 0.5164 | 0.5259 | 0.5010 |
| Sep 8, 2023 | 0.5294 | 0.0320 | 6.43% | 0.4974 | 0.5364 | 0.4974 |
| Sep 7, 2023 | 0.4845 | -0.0252 | -4.94% | 0.5097 | 0.5105 | 0.4574 |
| Sep 6, 2023 | 0.5094 | -0.0269 | -5.02% | 0.5363 | 0.5384 | 0.4990 |
| Sep 5, 2023 | 0.5386 | 0.0123 | 2.34% | 0.5263 | 0.5512 | 0.5153 |
| Sep 1, 2023 | 0.5176 | 0.0211 | 4.25% | 0.4965 | 0.5245 | 0.4916 |
Genprex, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, November 14, 2023 | ||
| Time (UTC) 20:04 | Country US
| Event Q3 2023 Genprex Inc Earnings Release Q3 2023 Genprex Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 23.8307 | 20.6701 | 17.9616 | 10.6827 | 12.3635 |
| Selling/General/Admin. Expenses, Total | 12.2951 | 11.6767 | 10.6359 | 8.7026 | 11.3862 |
| Research & Development | 11.5101 | 8.97087 | 7.30292 | 1.96701 | 0.97143 |
| Depreciation / Amortization | 0.02558 | 0.02253 | 0.02278 | 0.01307 | 0.00589 |
| Operating Income | -23.8307 | -20.6701 | -17.9616 | -10.6827 | -12.3635 |
| Net Income Before Taxes | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
| Net Income After Taxes | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
| Net Income Before Extra. Items | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
| Net Income | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
| Income Available to Common Excl. Extra. Items | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
| Income Available to Common Incl. Extra. Items | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
| Dilution Adjustment | |||||
| Diluted Net Income | -23.7406 | -20.665 | -17.9428 | -10.6548 | -12.3723 |
| Diluted Weighted Average Shares | 47.9521 | 47.0973 | 35.5229 | 16.027 | 13.771 |
| Diluted EPS Excluding Extraordinary Items | -0.49509 | -0.43877 | -0.5051 | -0.6648 | -0.89843 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -0.49509 | -0.43877 | -0.5051 | -0.6648 | -0.89843 |
| Interest Income (Expense), Net Non-Operating | 0.0901 | 0.00513 | 0.01881 | 0.02791 | -0.0088 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | |||
| Total Operating Expense | 8.03574 | 9.27125 | 6.82163 | 6.11065 | 5.77039 |
| Selling/General/Admin. Expenses, Total | 4.05499 | 3.95708 | 3.49665 | 2.51112 | 2.83692 |
| Research & Development | 3.97692 | 5.31015 | 3.3189 | 3.59331 | 2.92693 |
| Depreciation / Amortization | 0.00384 | 0.00402 | 0.00608 | 0.00622 | 0.00654 |
| Operating Income | -8.03574 | -9.27125 | -6.82163 | -6.11065 | -5.77039 |
| Interest Income (Expense), Net Non-Operating | 0.05555 | 0.06847 | 0.0556 | 0.02788 | 0.00574 |
| Net Income Before Taxes | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
| Net Income After Taxes | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
| Net Income Before Extra. Items | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
| Net Income | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
| Income Available to Common Excl. Extra. Items | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
| Income Available to Common Incl. Extra. Items | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
| Diluted Net Income | -7.98019 | -9.20277 | -6.76603 | -6.08278 | -5.76464 |
| Diluted Weighted Average Shares | 51.979 | 49.4716 | 48.0495 | 47.9847 | 47.8934 |
| Diluted EPS Excluding Extraordinary Items | -0.15353 | -0.18602 | -0.14081 | -0.12676 | -0.12036 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.15353 | -0.18602 | -0.14081 | -0.12676 | -0.12036 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 21.4732 | 39.1402 | 27.7044 | 2.97664 | 8.84707 |
| Cash and Short Term Investments | 20.9541 | 38.6289 | 27.3197 | 2.00249 | 8.60092 |
| Cash | 20.9541 | 38.6289 | 27.3197 | 2.00249 | 8.60092 |
| Prepaid Expenses | 0.48422 | 0.51135 | 0.38455 | 0.17172 | 0.23685 |
| Total Assets | 25.085 | 42.8623 | 31.3672 | 3.53423 | 9.26896 |
| Property/Plant/Equipment, Total - Net | 0.02303 | 0.04861 | 0.03944 | 0.04465 | 0.02435 |
| Intangibles, Net | 3.56703 | 3.66476 | 3.61267 | 0.4912 | 0.37945 |
| Other Long Term Assets, Total | 0.02182 | 0.00869 | 0.01074 | 0.02173 | 0.01809 |
| Total Current Liabilities | 2.81029 | 1.5853 | 0.45072 | 0.51068 | 0.38782 |
| Accounts Payable | 0.44293 | 0.9732 | 0.19297 | 0.43626 | 0.29507 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0.07443 | 0.09275 |
| Total Liabilities | 2.81029 | 1.5853 | 0.45072 | 0.51068 | 0.38782 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 22.2747 | 41.277 | 30.9165 | 3.02355 | 8.88114 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.04811 | 0.04787 | 0.04312 | 0.01926 | 0.01524 |
| Additional Paid-In Capital | 125.054 | 119.247 | 89.2956 | 43.4837 | 38.6906 |
| Retained Earnings (Accumulated Deficit) | -102.828 | -78.0179 | -58.4222 | -40.4795 | -29.8247 |
| Total Liabilities & Shareholders’ Equity | 25.085 | 42.8623 | 31.3672 | 3.53423 | 9.26896 |
| Total Common Shares Outstanding | 48.106 | 47.8747 | 43.1177 | 19.2638 | 15.2392 |
| Total Receivables, Net | 0.03485 | 0 | 0.00013 | 0.00066 | 0.0093 |
| Accounts Receivable - Trade, Net | 0.03485 | 0 | 0.00013 | 0.00066 | 0.0093 |
| Total Inventory | 0.80178 | ||||
| Other Current Liabilities, Total | 2.36736 | 0.6121 | 0.25776 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 19.9421 | 21.4732 | 26.3082 | 30.9008 | 35.7031 |
| Cash and Short Term Investments | 18.0828 | 20.9541 | 25.5161 | 30.053 | 34.5553 |
| Cash | 18.0828 | 20.9541 | 25.5161 | 30.053 | 34.5553 |
| Total Receivables, Net | 0 | 0.03485 | 0.03485 | 0.03217 | |
| Accounts Receivable - Trade, Net | 0 | 0.03485 | 0.03485 | 0.03217 | |
| Total Inventory | |||||
| Prepaid Expenses | 1.85934 | 0.48422 | 0.75728 | 0.8478 | 1.1156 |
| Total Assets | 23.3201 | 25.085 | 29.9458 | 34.5651 | 39.4094 |
| Property/Plant/Equipment, Total - Net | 0.01902 | 0.02303 | 0.02911 | 0.03533 | 0.04188 |
| Intangibles, Net | 3.33712 | 3.56703 | 3.58671 | 3.61897 | 3.65444 |
| Other Long Term Assets, Total | 0.02182 | 0.02182 | 0.02182 | 0.01 | 0.01 |
| Total Current Liabilities | 4.83522 | 2.81029 | 2.45731 | 2.15384 | 2.38482 |
| Accounts Payable | 2.21225 | 0.44293 | 0.68387 | 0.68332 | 1.25298 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 2.62296 | 2.36736 | 1.77344 | 1.47052 | 1.13184 |
| Total Liabilities | 4.83522 | 2.81029 | 2.45731 | 2.15384 | 2.38482 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 18.4849 | 22.2747 | 27.4885 | 32.4113 | 37.0246 |
| Common Stock | 0.05197 | 0.04811 | 0.04802 | 0.0479 | 0.04788 |
| Additional Paid-In Capital | 130.463 | 125.054 | 122.433 | 121.273 | 120.717 |
| Retained Earnings (Accumulated Deficit) | -112.031 | -102.828 | -94.9924 | -88.9097 | -83.7403 |
| Total Liabilities & Shareholders’ Equity | 23.3201 | 25.085 | 29.9458 | 34.5651 | 39.4094 |
| Total Common Shares Outstanding | 51.9741 | 48.106 | 48.0203 | 47.8983 | 47.8797 |
| Other Equity, Total |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -23.7406 | -19.5956 | -17.9428 | -10.6548 | -12.3723 |
| Cash From Operating Activities | -17.779 | -14.2849 | -13.9351 | -6.91872 | -6.84653 |
| Cash From Operating Activities | 0.02558 | 0.02253 | 0.02278 | 0.01307 | 0.00589 |
| Non-Cash Items | 4.73194 | 4.27821 | 4.24619 | 3.52998 | 5.43538 |
| Changes in Working Capital | 1.20414 | 1.00995 | -0.26128 | 0.19299 | 0.08454 |
| Cash From Investing Activities | 0.09773 | -0.0838 | -2.33725 | -0.9469 | -0.10332 |
| Capital Expenditures | -0.05974 | -0.07244 | -0.12799 | -0.14512 | -0.10332 |
| Cash From Financing Activities | 0.00643 | 25.6779 | 41.5895 | 1.26719 | 15.3895 |
| Issuance (Retirement) of Stock, Net | 0.00643 | 25.6779 | 41.5895 | 1.26719 | 15.3895 |
| Net Change in Cash | -17.6748 | 11.3092 | 25.3172 | -6.59843 | 8.43967 |
| Other Investing Cash Flow Items, Total | 0.15747 | -0.01136 | -2.20926 | -0.80178 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.20277 | -23.7406 | -16.9746 | -10.8918 | -5.30982 |
| Cash From Operating Activities | -6.93244 | -17.779 | -13.1926 | -8.62165 | -4.0717 |
| Cash From Operating Activities | 0.00402 | 0.02558 | 0.0195 | 0.01327 | 0.00673 |
| Non-Cash Items | 1.33212 | 4.73194 | 3.18436 | 2.0261 | 1.05744 |
| Cash Taxes Paid | |||||
| Cash Interest Paid | |||||
| Changes in Working Capital | 0.93421 | 1.20414 | 0.57811 | 0.23078 | 0.17395 |
| Cash From Investing Activities | -0.01963 | 0.09773 | 0.07805 | 0.0458 | -0.00184 |
| Capital Expenditures | -0.01963 | -0.05974 | -0.03974 | -0.02369 | -0.00184 |
| Other Investing Cash Flow Items, Total | 0.15747 | 0.11779 | 0.06949 | ||
| Cash From Financing Activities | 4.08078 | 0.00643 | 0.00175 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 4.08078 | 0.00643 | 0.00175 | 0 | |
| Net Change in Cash | -2.87128 | -17.6748 | -13.1128 | -8.57586 | -4.07354 |
| Financing Cash Flow Items | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Genprex, Inc. Company profile
About Genprex Inc
Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogene therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Genprex Inc revenues was not reported. Net loss increased 9% to $13.9M. Higher net loss reflects General and administrative increase of 13% to $8.8M (expense), Research and development increase of 3% to $5.1M (expense), Interest Income decrease of 76% to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.30.
| Industry: | Bio Therapeutic Drugs |
1601 Trinity Street, Bldg. B
Suite 3.322
78712
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com